EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • JanusMatrix Analysis
    • High Throughput Antibody Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • In Vitro Immunization Protocol (IVIP)
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Apr 12;9(7). PubMed PMID 23584251
Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference

Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Jul;9(7):1555-7. doi: 10.4161/hv.24833. Epub 2013 May 31.
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. Volume 9, Issue 5 May 2013:950–956.

Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense?

by epivax3 | Oct 22, 2016

Human Vaccines and Immunotherapy. Sep 2013.
Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice

by epivax3 | Oct 22, 2016

Hum Vaccin Immunother. 2013 Sep 17;9(10).
« Older Entries
Next Entries »

Recent Posts

  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!
  • EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™
  • EpiVax, Inc. Subsidiary, EpiVax Therapeutics Signs Exclusive Collaboration Agreement with GreenLight Biosciences to Develop Personalized Cancer Vaccines
  • #VaxGivesBack and 2022 Charitable Giving
  • EpiVax 2.0 and … Matching your Philanthropy!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562